Ray Therapeutics receives EMA PRIME status for gene therapy
The PRIME status for RTx-015 was granted based on preliminary Phase I/II safety and efficacy clinical data.
Drug Development
Regeneron Q1 2026 net income falls 10% to $727m
Arcera and Fosun sign MoU for neuroscience innovation
Rocket to sell PRV for $180m to advance gene therapy pipeline
BioMarin acquires Amicus Therapeutics for $4.8bn
FDA approves AstraZeneca’s Saphnelo for SLE
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Sun Pharma to acquire Organon for $11.75bn
